Klebsiella pneumoniae Infections - Pipeline Review, H2 2017

  • ID: 4418984
  • Report
  • 86 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acies Bio doo
  • Evaxion Biotech ApS
  • FOB Synthesis Inc
  • Melinta Therapeutics Inc
  • Peptilogics Inc
  • Phico Therapeutics Ltd
  • MORE
Klebsiella pneumoniae Infections - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H2 2017, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 23 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acies Bio doo
  • Evaxion Biotech ApS
  • FOB Synthesis Inc
  • Melinta Therapeutics Inc
  • Peptilogics Inc
  • Phico Therapeutics Ltd
  • MORE
Introduction

Klebsiella pneumoniae Infections - Overview

Klebsiella pneumoniae Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Klebsiella pneumoniae Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development

Acies Bio doo

Appili Therapeutics

Debiopharm International SA

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

FOB Synthesis Inc

ImmunoClin Corp

Innovation Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Nosopharm SAS

Peptilogics Inc

Pfizer Inc

Phico Therapeutics Ltd

Sarepta Therapeutics Inc

Shionogi & Co Ltd

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Klebsiella pneumoniae Infections - Drug Profiles

Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile

ASN-300 - Drug Profile

ATI-1503 - Drug Profile

CA-824 - Drug Profile

CC-1807 - Drug Profile

cefiderocol - Drug Profile

Debio-1454 - Drug Profile

EBX-004 - Drug Profile

FPI-1465 - Drug Profile

FSI-1671 - Drug Profile

FSI-1686 - Drug Profile

GN Snare - Drug Profile

GYR-12 - Drug Profile

IBN-1 - Drug Profile

interleukin-22 - Drug Profile

kelokardin - Drug Profile

Klebsiella pneumonia vaccine - Drug Profile

Klebsiella pneumoniae vaccine - Drug Profile

Klebsiella pneumoniae vaccine - Drug Profile

Klebsiella pneumoniae vaccine - Drug Profile

mirandamycin - Drug Profile

NCL-195 - Drug Profile

NOSO-95179 - Drug Profile

Onc-72 - Drug Profile

OTP-602 - Drug Profile

Peptides for Infectious Diseases - Drug Profile

PT-4 - Drug Profile

RXP-873 - Drug Profile

Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile

Small Molecules for Bacterial and Fungal Infections - Drug Profile

Small Molecules for Bacterial Infections - Drug Profile

Small Molecules for Bacterial Infections - Drug Profile

Small Molecules for Klebsiella pneumoniae Infections - Drug Profile

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile

Small Molecules to Inhibit Lipopolysaccharide for Bacterial and Nosocomial Infections - Drug Profile

tebipenem pivoxil - Drug Profile

TP-6076 - Drug Profile

WLBU-2 - Drug Profile

Klebsiella pneumoniae Infections - Dormant Projects

Klebsiella pneumoniae Infections - Discontinued Products

Klebsiella pneumoniae Infections - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Klebsiella pneumoniae Infections - Pipeline by Acies Bio doo, H2

Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics, H2

Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA, H2

Klebsiella pneumoniae Infections - Pipeline by Evaxion Biotech ApS, H2

Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2

Klebsiella pneumoniae Infections - Pipeline by FOB Synthesis Inc, H2

Klebsiella pneumoniae Infections - Pipeline by ImmunoClin Corp, H2

Klebsiella pneumoniae Infections - Pipeline by Innovation Pharmaceuticals Inc, H2

Klebsiella pneumoniae Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H2

Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, H2

Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H2

Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, H2

Klebsiella pneumoniae Infections - Pipeline by Pfizer Inc, H2

Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, H2

Klebsiella pneumoniae Infections - Pipeline by Sarepta Therapeutics Inc, H2

Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, H2

Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H2

Klebsiella pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2

Klebsiella pneumoniae Infections - Dormant Projects, H2

Klebsiella pneumoniae Infections - Discontinued Products, H2

List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Top 10 Molecule Types, H2

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acies Bio doo
  • Appili Therapeutics
  • Debiopharm International SA
  • Evaxion Biotech ApS
  • F. Hoffmann-La Roche Ltd
  • FOB Synthesis Inc
  • ImmunoClin Corp
  • Innovation Pharmaceuticals Inc
  • Kyorin Pharmaceutical Co Ltd
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Peptilogics Inc
  • Pfizer Inc
  • Phico Therapeutics Ltd
  • Sarepta Therapeutics Inc
  • Shionogi & Co Ltd
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll